For example, some individuals have no symptoms, while others may have a manifestation that is rapidly more progressive and severe. For many NF-1 patients, a primary concern is the disfigurement caused by cutaneous/dermal neurofibromas, pigmented lesions, and the occasional limb abnormalities. However, there are many more severe complications caused by NF-1 like increased cancer risk, a plexiform neurofibroma has a 10-15% chance of developing into a MPNST (Malignant Peripheral Nerve Sheath Tumour) . Many NF patients live perfectly normal and uninterrupted lives. Epidemiology
NF-1 is estimated to affect around 25,000 people in the UK. See also
Neurofibromatosis type II

References
External links

Friedman, J. M. (1993). "Neurofibromatosis 1". GeneReviews®. University of Washington, Seattle. PMID 20301288. Legius, Eric; Stevenson, David (1993). "Legius Syndrome". GeneReviews®. University of Washington, Seattle. PMID 20945555.
Perrigo settled its patent litigation with Valeant and Dow. References
External links
"Benzoyl peroxide mixture with clindamycin phosphate". Drug Information Portal. U.S. National Library of Medicine.